Capivasertib: as the comparator
2 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerRecruitingNCT06982521Phase 3Report a problem
- Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast CancerRecruitingNCT06837792Phase 2Report a problem